Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.82 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.82 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.82 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.82 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.82 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.82 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.82 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.82 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.82 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | CASP7 | P55210 | 3/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25711249 | 1.00 | GPBAR1 (0.82) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| SCHEMBL18733391 | 1.00 | GPBAR1 (0.82) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| SCHEMBL22769482 | 1.00 | GPBAR1 (0.82) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| SCHEMBL25710069 | 1.00 | GPBAR1 (0.82) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| SCHEMBL13592769 | 1.00 | GPBAR1 (0.82) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| SCHEMBL19713107 | 1.00 | GPBAR1 (0.82) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| SCHEMBL28367672 | 0.90 | GPBAR1 (0.77) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL25023044 | 0.90 | GPBAR1 (1.00) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| SCHEMBL4740095 | 0.90 | GPBAR1 (0.83) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 | |
| Ursocholanic Acid SCHEMBL190519 | 0.90 | GPBAR1 (1.00) | GPBAR1EPHA2HSD17B10TDP1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12389901-B2 | Temperature-responsive virus storage system | FERRING VENTURES LTD (GB) | 2025-08-19 | — | — | US | claimed |
| US-20250089702-A1 | TEMPERATURE-RESPONSIVE VIRUS STORAGE SYSTEM | FERRING VENTURES LTD (GB) | 2025-03-20 | — | — | US | claimed |
| US-20240117379-A1 | TEMPERATURE-RESPONSIVE VIRUS STORAGE SYSTEM | FERRING VENTURES LTD (GB) | 2024-04-11 | — | — | US | claimed |
| US-20240043873-A1 | TEMPERATURE-RESPONSIVE VIRUS STORAGE SYSTEM | FERRING VENTURES LTD (GB) | 2024-02-08 | — | — | US | claimed |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2019-03-28 | — | — | US | claimed |
| WO-2017075052-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2017-05-04 | — | — | WO | claimed |
| WO-2017042634-A2 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES AND ANALOGS THEREOF FOR TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA, GLIOBLASTOMA, AND OVARIAN CARCINOMA BY INDUCTION OF DNA DAMAGE AND STALLING OF CELL CYCLE | DEL MAR PHARMACEUTICALS (CA) | 2017-03-16 | — | — | WO | claimed |
| US-20160158186-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF TO TREAT RECURRENT MALIGNANT GLIOMA OR PROGRESSIVE SECONDARY BRAIN TUMOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2016-06-09 | — | — | US | claimed |
| EP-3003321-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF TO TREAT RECURRENT MALIGNANT GLIOMA OR PROGRESSIVE SECONDARY BRIAN TUMOR | Del Mar Pharmaceuticals (CA) | 2016-04-13 | — | — | EP | claimed |
| US-20160045502-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2016-02-18 | — | — | US | claimed |
| EP-2983674-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | Brown, Dennis M. (US) | 2016-02-17 | — | — | EP | claimed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | claimed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | claimed |
| WO-2014194312-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF TO TREAT RECURRENT MALIGNANT GLIOMA OR PROGRESSIVE SECONDARY BRIAN TUMOR | DEL MAR PHARMACEUTICALS (CA) | 2014-12-04 | — | — | WO | claimed |
| WO-2014168986-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2014-10-16 | — | — | WO | claimed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | claimed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11629166-B2 | Compound for treating clostridium difficile | ASTON UNIVERSITY (GB) | 2023-04-18 | — | — | US | disclosed |
| EP-2044100-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | Novartis AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008009407-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | GPBAR1 3311/4885EPHA2 2735/4885HSD17B10 3101/4885 |
| US-20160158186-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF TO TREAT RECURRENT MALIGNANT GLIOMA OR PROGRESSIVE SECONDARY BRAIN TUMOR | DDOST, DAD1, PHGDH | GPBAR1 3301/4885EPHA2 2910/4885HSD17B10 464/4885 |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | GPBAR1 3627/4885EPHA2 3489/4885HSD17B10 833/4885 |
| US-20160045502-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | GPBAR1 3311/4885EPHA2 2735/4885HSD17B10 3101/4885 |
| US-11629166-B2 | Compound for treating clostridium difficile | DSTN, DAD1, DDOST | GPBAR1 77/4885EPHA2 1043/4885HSD17B10 1380/4885 |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DDOST, DCLRE1A, OGG1 | GPBAR1 4208/4885EPHA2 3091/4885HSD17B10 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.